secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aspire Biopharma Holdings, Inc. (ASBP)
CIK:        0001847345
Form:       8-K
Filed at:   2025-02-20T23:59:59+00:00
Accession:  0001493152-25-007732
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 2.03, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aspire Biopharma closes SPAC merger, lists on Nasdaq; enters $100M equity line
------------------------------------------------------------------------------

- Completed business combination with PowerUp Acquisition Corp.; began trading on Nasdaq Feb 20 under ASBP/ASBPW.
- Proceeds from transaction total approx $3.8M including trust account and PIPE financing.
- Entered $100M ELOC agreement with Arena; 96% of VWAP with $4.00 floor; 1,893,473 commitment shares issued.
- Lead product is fast-absorbing aspirin for cardiology emergencies; plans FDA fast track 505(b)(2) NDA.
- Management led by CEO Kraig Higginson; board of seven directors including Michael Howe, Gary E. Stein.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847345/000149315225007732/0001493152-25-007732-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847345/000149315225007732/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-007732

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer